Individualized rituximab treatment for neuromyelitis optica spectrum disorders

JAMA Neurology

Volumn 70, Issue 9, 2013, Pages 1102-1104

  McKeon, Andrew ^a   Pittock, Sean ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; CD19 ANTIGEN; CD27 ANTIGEN; IMMUNOGLOBULIN G; RITUXIMAB; AUTOANTIBODY; MONOCLONAL ANTIBODY;

DISEASE EXACERBATION; DOSE RESPONSE; EDITORIAL; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOLOGICAL MONITORING; IMMUNOPROPHYLAXIS; INDUCTION CHEMOTHERAPY; INFECTION; INFUSION RELATED REACTION; MEDICATION COMPLIANCE; MEMORY CELL; MYELOOPTIC NEUROPATHY; NEUROPROTECTION; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SINGLE DRUG DOSE; B LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGY; METABOLISM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIGENS, CD27; AQUAPORIN 4; AUTOANTIBODIES; B-LYMPHOCYTES; HUMANS; NEUROMYELITIS OPTICA;

EID: 84883746093     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.3583     Document Type: Editorial

References (19)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. (Pubitemid 47238676)
2. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219-1220. (Pubitemid 28473439)
3. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272.
4. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128-1133.
5. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-1448.
6. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659-666.
7. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18(7):1022-1026.
8. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-1315.
9. Kim S-H, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011;68(11):1412-1420.
10. Kim S-H, Huh S-Y, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder [published online July 29, 2013]. JAMA Neurol. 2013. doi:10.1001/jamaneurol. 2013.3071.
11. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75(16):1423-1427.
12. Beum PV, Peek EM, LindorferMA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011;187(6):3438-3447.
13. Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev. 2010;9(12):801-803.
14. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580-2589. (Pubitemid 39062719)
15. Mahévas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013;123(1):432-442.
16. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77(6):589-593.
17. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394-397.
18. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701-3706.
19. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554-562.